10% off your first order — code WELCOME10 · For research use only · Not for human consumption · All sales final
Home/Research/GLP-1 Research Peptides Explained
Mar 10, 2026 · Research use only

GLP-1 Research Peptides Explained

The metabolic-research cluster everyone's searching for: how semaglutide, tirzepatide, and retatrutide differ at the receptor level.

GLP-1 receptor agonists are the most-searched cluster in metabolic peptide research. Semaglutide, tirzepatide, and retatrutide are studied in appetite-regulation, energy-expenditure, and insulin-signaling models — but they differ in which receptors they target. Here's the breakdown. For in-vitro laboratory research only.

Research-use-only reference standards. These compounds are not drugs or products for human or veterinary use.

Semaglutide — single agonist (GLP-1)

Semaglutide is a GLP-1 receptor agonist. In research it's studied for its effects on the GLP-1 pathway, which is involved in appetite signaling and glucose-dependent insulin regulation. See the semaglutide research kit.

Tirzepatide — dual agonist (GIP + GLP-1)

Tirzepatide activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) in addition to GLP-1. The dual-agonist design is a major focus of current metabolic research. See the tirzepatide research kit.

Retatrutide — triple agonist (GIP + GLP-1 + glucagon)

Retatrutide (LY3437943) targets three receptors — adding glucagon-receptor activity to the GIP/GLP-1 pair. It's the newest and most-discussed compound in the cluster. See the retatrutide research kit.

Cagrilintide combinations

Cagrilintide, an amylin analog, is studied in combination with semaglutide (the cagrilintide + semaglutide blend) for complementary metabolic-pathway research.

Quick comparison

  • Semaglutide — GLP-1 only (single agonist)
  • Tirzepatide — GIP + GLP-1 (dual agonist)
  • Retatrutide — GIP + GLP-1 + glucagon (triple agonist)

Frequently asked questions

What's the difference between semaglutide and tirzepatide?

Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist that also activates the GIP receptor. See our full semaglutide vs tirzepatide comparison.

What is retatrutide?

Retatrutide (LY3437943) is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors — the newest compound in the GLP-1 research cluster.

Are these GLP-1 compounds sold for research only?

Yes. All are supplied as research-use-only reference standards for in-vitro laboratory study, supplied lyophilized in multi-vial research kits.